A Systematic Review of Candidate miRNAs, Its Targeted Genes and Pathways in Chronic Myeloid Leukemia-An Integrated Bioinformatical Analysis

被引:11
作者
Elias, Marjanu Hikmah [1 ]
Syed Mohamad, Syarifah Faezah [1 ,2 ]
Abdul Hamid, Nazefah [1 ]
机构
[1] Univ Sains Islam Malaysia, Fac Med & Hlth Sci, Nilai, Malaysia
[2] Univ Teknol MARA Cawangan Pahang, Fac Appl Sci, Jengka, Malaysia
关键词
chronic myeloid leukemia; genes; pathways; microRNA; BCR-ABL1; CELL-PROLIFERATION; IMATINIB; PROMOTES; EXPRESSION; APOPTOSIS;
D O I
10.3389/fonc.2022.848199
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic myeloid leukaemia is blood cancer due to a reciprocal translocation, resulting in a BCR-ABL1 oncogene. Although tyrosine kinase inhibitors have been successfully used to treat CML, there are still cases of resistance. The resistance occurred mainly due to the mutation in the tyrosine kinase domain of the BCR-ABL1 gene. However, there are still many cases with unknown causes of resistance as the etiopathology of CML are not fully understood. Thus, it is crucial to figure out the complete pathogenesis of CML, and miRNA can be one of the essential pathogeneses. The objective of this study was to systematically review the literature on miRNAs that were differentially expressed in CML cases. Their target genes and downstream genes were also explored. An electronic search was performed via PubMed, Scopus, EBSCOhost MEDLINE, and Science Direct. The following MeSH (Medical Subject Heading) terms were used: chronic myeloid leukaemia, genes and microRNAs in the title or abstract. From 806 studies retrieved from the search, only clinical studies with in-vitro experimental evidence on the target genes of the studied miRNAs in CML cells were included. Two independent reviewers independently scrutinised the titles and abstracts before examining the eligibility of studies that met the inclusion criteria. Study design, sample size, sampling type, and the molecular method used were identified for each study. The pooled miRNAs were analysed using DIANA tools, and target genes were analysed with DAVID, STRING and Cytoscape MCODE. Fourteen original research articles on miRNAs in CML were included, 26 validated downstream genes and 187 predicted target genes were analysed and clustered into 7 clusters. Through GO analysis, miRNAs' target genes were localised throughout the cells, including the extracellular region, cytosol, and nucleus. Those genes are involved in various pathways that regulate genomic instability, proliferation, apoptosis, cell cycle, differentiation, and migration of CML cells.
引用
收藏
页数:13
相关论文
共 45 条
[1]   BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia [J].
Agatheeswaran, S. ;
Singh, S. ;
Biswas, S. ;
Biswas, G. ;
Pattnayak, N. Chandra ;
Chakraborty, S. .
LEUKEMIA, 2013, 27 (07) :1578-1580
[2]   Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth [J].
Agirre, Xabier ;
Jimenez-Velasco, Antonio ;
San Jose-Eneriz, Edurne ;
Garate, Leire ;
Bandres, Eva ;
Cordeu, Lucia ;
Aparicio, Oscar ;
Saez, Borja ;
Navarro, German ;
Vilas-Zornoza, Amaia ;
Perez-Roger, Ignacio ;
Garcia-Foncillas, Jesus ;
Torres, Antonio ;
Heiniger, Anabel ;
Jose Calasanz, Maria ;
Fortes, Puri ;
Roman-Gomez, Jose ;
Prosper, Felipe .
MOLECULAR CANCER RESEARCH, 2008, 6 (12) :1830-1840
[3]   The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy [J].
Ardito, Fatima ;
Giuliani, Michele ;
Perrone, Donatella ;
Troiano, Giuseppe ;
Lo Muzio, Lorenzo .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 (02) :271-280
[4]   Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells [J].
Babashah, Sadegh ;
Sadeghizadeh, Majid ;
Hajifathali, Abbas ;
Tavirani, Mostafa Rezaei ;
Zomorod, Mina Soufi ;
Ghadiani, Mojtaba ;
Soleimani, Masoud .
INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (03) :579-589
[5]   Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update [J].
Bavaro, Luana ;
Martelli, Margherita ;
Cavo, Michele ;
Soverini, Simona .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (24)
[6]   Molecular Pathways: BCR-ABL [J].
Cilloni, Daniela ;
Saglio, Giuseppe .
CLINICAL CANCER RESEARCH, 2012, 18 (04) :930-937
[7]   Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia [J].
Di Rora, Andrea Ghelli Luserna ;
Beeharry, Neil ;
Imbrogno, Enrica ;
Ferrari, Anna ;
Robustelli, Valentina ;
Righi, Simona ;
Sabattini, Elena ;
Falzacappa, Maria Vittoria Verga ;
Ronchini, Chiara ;
Testoni, Nicoletta ;
Baldazzi, Carmen ;
Papayannidis, Cristina ;
Abbenante, Maria Chiara ;
Marconi, Giovanni ;
Paolini, Stefania ;
Parisi, Sarah ;
Sartor, Chiara ;
Fontana, Maria Chiara ;
De Matteis, Serena ;
Iacobucci, Ilaria ;
Pelicci, Pier Giuseppe ;
Cavo, Michele ;
Yen, Timothy J. ;
Martinelli, Giovanni .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[8]   The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia [J].
Di Stefano, Carla ;
Mirone, Giovanna ;
Perna, Stefania ;
Marfe, Gabriella .
ONCOLOGY REPORTS, 2016, 35 (02) :614-624
[9]   Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients [J].
Elias, Marjanu Hikmah ;
Azlan, Husin ;
Sulong, Sarina ;
Baba, Abdul Aziz ;
Ankathil, Ravindran .
CANCER REPORTS, 2018, 1 (02)
[10]  
Elias Marjanu Hikmah, 2018, Cardiovascular & Hematological Disorders - Drug Targets, V18, P234, DOI 10.2174/1871529X18666180419101416